AI English summary of an SEC filing — figures as filed
Gilead Sciences GILDGilead said total revenues for 2023 were $27.1 billion, down 1% from 2022, as lower Veklury sales were largely offset by higher HIV and Oncology sales. HIV product sales rose 6% to $18.2 billion.
Key points
AI summaryGilead said total revenues for 2023 were $27.1 billion, down 1% from 2022, as lower Veklury sales were largely offset by higher HIV and Oncology sales. HIV product sales rose 6% to $18.2 billion.
The company said net income attributable to Gilead for 2023 was $5.7 billion and diluted earnings per share attributable to Gilead was $4.50, up from $4.6 billion and $3.64 in 2022. It cited lower IPR&D impairment expenses, lower net unrealized losses on equity investments and higher interest income as factors behind the increase.
Gilead said it had about $5.9 billion allocated to its indefinite-lived IPR&D intangible asset related to Trodelvy for metastatic NSCLC as of December 31, 2023. It said it expects to complete its interim impairment assessment in Q1 2024 and that it is unable to reasonably estimate any impairment charge.
Gilead said net cash provided by operating activities was $8.0 billion in 2023, down from $9.1 billion in 2022. It said it used cash in financing activities in 2023 for debt repayments of $2.3 billion, dividend payments of $3.8 billion and common stock repurchases of $1.0 billion, partially offset by net proceeds of $2.0 billion from senior unsecured notes issued.
Key figures
Fiscal year ended December 31, 2023
- Revenue
- $27.1B
- Operating income
- $7.6B
- Net income
- $5.7B
- EPS
- $4.50
- Operating cash flow
- $8.0B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Gilead total revenues $27.1 billion in 2023, down 1%
Gilead said total revenues for 2023 were $27.1 billion, down 1% from 2022, as lower Veklury sales were largely offset by higher HIV and Oncology sales. HIV product sales rose 6% to $18.2 billion.
Source · Based on the MD&A text of the filing
Gilead net income attributable to Gilead $5.7 billion, diluted EPS $4.50 in 2023
The company said net income attributable to Gilead for 2023 was $5.7 billion and diluted earnings per share attributable to Gilead was $4.50, up from $4.6 billion and $3.64 in 2022. It cited lower IPR&D impairment expenses, lower net unrealized losses on equity investments and higher interest income as factors behind the increase.
Source · Based on the MD&A text of the filing
Trodelvy NSCLC IPR&D asset about $5.9 billion to be tested for impairment in Q1 2024
Gilead said it had about $5.9 billion allocated to its indefinite-lived IPR&D intangible asset related to Trodelvy for metastatic NSCLC as of December 31, 2023. It said it expects to complete its interim impairment assessment in Q1 2024 and that it is unable to reasonably estimate any impairment charge.
Source · Based on the MD&A text of the filing
Operating cash flow $8.0 billion and financing cash outflow in 2023
Gilead said net cash provided by operating activities was $8.0 billion in 2023, down from $9.1 billion in 2022. It said it used cash in financing activities in 2023 for debt repayments of $2.3 billion, dividend payments of $3.8 billion and common stock repurchases of $1.0 billion, partially offset by net proceeds of $2.0 billion from senior unsecured notes issued.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…